Unity Biotechnology
Market Cap
€246.9m
Last Updated
2020/03/30 00:03 UTC
Data Sources
Company Financials +
Executive Summary
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span.
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and overvalued.
Share Price & News
How has Unity Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 9U9's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
12.0%
9U9
11.2%
DE Biotechs
7.3%
DE Market
1 Year Return
-28.1%
9U9
-5.1%
DE Biotechs
-17.7%
DE Market
Return vs Industry: 9U9 underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: 9U9 underperformed the German Market which returned -17.7% over the past year.
Shareholder returns
| 9U9 | Industry | Market | |
|---|---|---|---|
| 7 Day | 12.0% | 11.2% | 7.3% |
| 30 Day | -5.4% | -5.3% | -17.9% |
| 90 Day | -19.5% | -21.9% | -25.8% |
| 1 Year | -28.1%-28.1% | -4.9%-5.1% | -15.1%-17.7% |
| 3 Year | n/a | 17.7%16.5% | -18.7%-25.6% |
| 5 Year | n/a | -5.1%-7.5% | -17.7%-29.0% |
Price Volatility Vs. Market
How volatile is Unity Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Unity Biotechnology undervalued compared to its fair value and its price relative to the market?
2.25x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 9U9's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 9U9's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 9U9 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 9U9 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 9U9's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 9U9 is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
58.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 9U9's forecast earnings growth is above the savings rate (-0.4%).
Earnings vs Market: Insufficient data to determine if 9U9's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 9U9's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 9U9's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9U9 is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Unity Biotechnology performed over the past 5 years?
-7.6%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 9U9 is currently unprofitable.
Growing Profit Margin: 9U9 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 9U9's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 9U9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9U9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 9U9 has a negative Return on Equity (-68.08%), as it is currently unprofitable.
Next Steps
Financial Health
How is Unity Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 9U9's short term assets ($129.5M) exceed its short term liabilities ($17.2M).
Long Term Liabilities: 9U9's short term assets ($129.5M) exceed its long term liabilities ($13.3M).
Debt to Equity History and Analysis
Debt Level: 9U9 is debt free.
Reducing Debt: 9U9 has not had any debt for past 5 years.
Balance Sheet
Inventory Level: 9U9 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 9U9's debt is not covered by short term assets (assets are -18498.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9U9 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 9U9 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Unity Biotechnology's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 9U9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 9U9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9U9's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9U9's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 9U9's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average management tenure
CEO
Anirvan Ghosh
no data
Tenure
Dr. Anirvan Ghosh, Ph.D. serves as Chief Executive Officer of Unity Biotechnology, Inc. since March 20, 2020. Dr. Ghosh had been Senior Vice President of Research and Early Development at Biogen Inc. since ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.33yrs | US$2.86m | 4.98% $12.3m | |
| Chief Medical Officer | 4.17yrs | US$951.85k | 0.90% $2.2m | |
| Chief Executive Officer | no data | no data | no data | |
| 9.17yrs | no data | no data | ||
| 9.17yrs | no data | no data | ||
| 9.17yrs | no data | no data | ||
| Chief Financial Officer | 2.5yrs | US$1.29m | 0.24% $587.7k | |
| Senior Vice President of Operations | 2.92yrs | no data | no data | |
| Chief Scientific Officer | 4.25yrs | no data | 0.71% $1.7m | |
| General Counsel & Corporate Secretary | 2.75yrs | no data | 0.044% $109.3k |
4.2yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 9U9's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.33yrs | US$2.86m | 4.98% $12.3m | |
| Independent Director | 8.33yrs | no data | no data | |
| Independent Director | 5yrs | US$551.11k | 0.021% $52.7k | |
| Lead Independent Director | no data | US$933.01k | 0.0069% $16.9k | |
| Chairman | 4.17yrs | US$2.73m | 1.8% $4.4m | |
| Independent Director | 8.33yrs | US$551.83k | 0.24% $586.0k | |
| Independent Director | 2.92yrs | US$167.90k | 0.18% $439.5k | |
| Independent Director | 2yrs | US$285.51k | no data | |
| Independent Director | 1.25yrs | US$533.51k | no data |
4.6yrs
Average Tenure
52yo
Average Age
Experienced Board: 9U9's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.3%.
Top Shareholders
Company Information
Unity Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Unity Biotechnology, Inc.
- Ticker: 9U9
- Exchange: DB
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$273.776m
- Listing Market Cap: US$246.918m
- Shares outstanding: 47.61m
- Website: https://www.unitybiotechnology.com
Number of Employees
Location
- Unity Biotechnology, Inc.
- 3280 Bayshore Boulevard
- Suite 100
- Brisbane
- California
- 94005
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| UBX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 2018 |
| 9U9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2018 |
| 0YC0 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2018 |
Biography
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/30 00:03 |
| End of Day Share Price | 2020/03/27 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.